Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Colorcon
Moodys
Medtronic
McKesson

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Imeglimin

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Imeglimin?

Imeglimin is an investigational drug.

There have been 6 clinical trials for Imeglimin. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2013.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Liver Diseases. The leading clinical trial sponsors are Poxel SA and [disabled in preview].

There are six US patents protecting this investigational drug and one hundred and forty-seven international patents.

Recent Clinical Trials for Imeglimin
TitleSponsorPhase
Pharmacokinetics of Imeglimin in Hepatic Impaired SubjectsPoxel SAPhase 1
Bioequivalence of Imeglimin Tablet FormulationsPoxel SAPhase 1
Effect of Cimetidine on the PK of ImegliminPoxel SAPhase 1

See all Imeglimin clinical trials

Clinical Trial Summary for Imeglimin

Top disease conditions for Imeglimin
Top clinical trial sponsors for Imeglimin

See all Imeglimin clinical trials

US Patents for Imeglimin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Imeglimin   Start Trial Biguanide compositions and methods of treating metabolic disorders ELCELYX THERAPEUTICS, INC. (San Diego, CA)   Start Trial
Imeglimin   Start Trial Separation of triazine derivatives enantiomers using tartaric acid Poxel (Lyons, FR)   Start Trial
Imeglimin   Start Trial Biguanide compositions and methods of treating metabolic disorders Elcelyx Therapeutics, Inc (San Diego, CA)   Start Trial
Imeglimin   Start Trial Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization Poxel (Lyons, FR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Imeglimin

Drugname Country Document Number Estimated Expiration Related US Patent
Imeglimin Argentina 091089 2031-01-07   Start Trial
Imeglimin Argentina 091739 2031-01-07   Start Trial
Imeglimin Australia 2011317140 2030-10-19   Start Trial
Imeglimin Australia 2011317143 2030-10-19   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Moodys
Merck
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.